Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Wedbush Adjusts Sage Therapeutics' PT to $9 From $15, Maintains Neutral Rating
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics' Stock Dives as Failed Trial Hits Biogen Collaboration
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
SAGE Therapeutics: Hold Rating Following SAGE-324 Clinical Trial Setback
Sage Therapeutics Shares Tumble Premarket on Essential Tremor Study Failure
Express News | Needham Reiterates Hold on Sage Therapeutics
Express News | Sage Therapeutics Inc : RBC Cuts Target Price to $10 From $12
Top Premarket Decliners
Biogen, Sage Discontinue Neuro Candidate After Mid-stage Setback
Express News | Sage Therapeutics Shares Down About 28% Premarket After Co, Partner Biogen to Scrap Development of Neurological Disorder Drug
Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails
Express News | Sage Therapeutics Shares Are Trading Lower After the Phase 2 KINETIC 2 Study of SAGE-324 Did Not Demonstrate a Statistically Significant Dose-response Relationship on the Primary Endpoint
Express News | Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint
Express News | Sage Therapeutics Inc: Do Not Plan to Conduct Further Clinical Development of Sage-324 in Et
Express News | Biogen Inc - Sage and Biogen to Close Ongoing Sage-324 Study
Express News | Biogen Inc - Sage-324 Did Not Show Significant Dose-Response
Express News | Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint
Express News | Sage Therapeutics and Biogen Announce Topline Results From Phase 2 Kinetic 2 Study of Sage-324 (Biib124) for the Treatment of Essential Tremor